The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Open accessAbstract
Amyloid plaques and neurofibrillary tangles (NFTs) are the pathological hallmarks of Alzheimer disease (AD). There is controversy regarding the use of current diagnostic criteria for AD and whether amyloid plaques and NFTs contribute to cognitive impairment. Because AD is specific to humans, rigorous and comprehensiveclinicopathologic studies are necessary to test and refine hypotheses of AD diagnosis and pathogenesis. Neither the clinical nor the pathological aspects of AD evolve in a linear manner, but thepredictable sequence of AD pathology allows for stage-based correlations with cognitive deterioration. We discuss subsets of patients with clinical dementia who lack amyloid plaques and NFTs and, conversely, whether individuals without antemortem cognitive impairment can harbor severe AD-type pathological findings at autopsy. There are many medical, technical, and anatomical challenges to clinicopathologic studies in AD. For example, at least two thirds of persons older than 80 years have non-AD brain diseases that can effect on cognitive function. We argue that existing data strongly support the hypothesis that both amyloid plaques and NFTs contribute to cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“leading to dysfunction and loss of synapses and eventual neuronal death1,2.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by an accumulation of senile plaques (SP) [composed mostly of fibrillary amyloid beta-peptide (Aβ) and dystrophic neurites] and neurofibrillary tangles (NFT) [composed of hyperphosphorylated tau protein] in the brain”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinically, AD is characterized by several features, notably a progressive cognitive decline involving loss of memory and higher executive functioning1.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“It is expected that many persons die with brains that exhibit AD neuropathologic change in the preclinical phase of AD; indeed, data support the modeled expectations (44, 142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
The cited source says what the claim attributes to it.
In the citing paper
“Evaluation of AD status was conducted by the AD Center Neuropathology and Clinical Cores using guidelines set forth by the National Institute on Aging Reagan Institute that included evaluation of neurofibrillary tangles and neuritic senile plaques [36–38].”
From Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts (2016) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, the first pathological insults to neurons in AD and aMCI occur at pre- and post-synaptic membranes1,3.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, this is precisely the observation reported by one of the largest autopsy series to date (142) and is well supported by AD biomarker studies (143-145).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“It is important to emphasize that, among thousands of cases from dozens of CPC studies worldwide, there never has been a report of a thoroughly documented individual with truly “end-stage” neocortical NFT pathology who lacked antemortem cognitive impairment proximal to death (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“However, not all Braak stage VI brains were the same; there was significant variation in NFT burden in these cases (142, 151).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“In a review of 11 different studies comprising 555 subjects without dementia, a total of 12 brains were assessed as Braak stage V (2.2%); 3 were assessed as Braak stage VI (0.5%) (142).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [142]
In the citing paper
“There have been many clinicopathological studies that have correlated amyloid plaques with cognitive deficits in AD, with an emerging picture that the strongest correlation exists in the earliest stages of the disease and this association greatly weakens as NFTs and neocortical degeneration become more widespread [9, 102, 103, 157, 160, 169].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationLOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS
Scoville, W. B., & Milner, B. (1957) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.20.1.11 · Cited by 7,322
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Research works printed but not linked: 1
- Centers for Disease Control and Prevention. Prevalence of stroke-United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–74
Cited by
Sorted by citations
Items 601–638 of 638
Khundakar, A. A., & Thomas, A. J. (2015) · Advances in Alzheimer's disease · doi:10.3233/978-1-61499-542-5-187 · Cited by 1
Physical Activity and the Myokine Irisin in Non-pharmacological Treatment of Alzheimer Disease
Gibizov, Y. A., Vagapova, L. B., Aguzarova, A. O., Nazarova, J. V., Zotkina, Y. A., Atamanyuk, E. A., Rodikova, M. M., Timergaleev, R. N., Kupriyanov, A. M., Chuprina, A. A., et al. (2025) · Russian Journal of Physiotherapy Balneology and Rehabilitation · doi:10.17816/rjpbr677844
Phycobiliproteins-algae-derived pigments: Advances in research on the therapeutic potential
Jaiswal, M., Lal, R., Pandey, S., Amin, N., Pandey, A., & Kannaujiya, V. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24017-1.00008-7
Erdoğan, H., DEĞER, T. B., ERDOĞAN, S., Paşa, S., Balıkçı, C., Tendar, İ., Kizilkanat, A. İ., Dinç, P., & Ural, K. (2025) · Current Perspectives on Health Sciences · doi:10.58208/cphs.1607803
Genetics of PLCG2 expression and splicing relative to Alzheimer’s disease risk
Turner, A. K., Dotson, K., Qiao, Q., Cain, K., Simpson, J. F., Fardo, D. W., & Estus, S. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00007-8 · Cited by 1
Role of diabetes and altered metabolic homeostasis in age-related dementia
Biswas, T., Ahmed, M. A., Bhowmick, S., & Mondal, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00028-1
Evaluation of cognitive performance within the disease course of Alzheimer´s
Rettenwander, L. A. E. (2014) · Utrecht University Repository (Utrecht University)
Torso, M., Ridgway, G. R., Valotti, M., Hardingham, I., & Chance, S. A. (2023) · Figshare · doi:10.6084/m9.figshare.24248059
Xu, G. M., Fromholt, S., Chakrabarty, P., Zhu, F., Liu, X., Pace, M. C., Koh, J., GOLDE, T. E., Levites, Y., Lewis, J. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12097272
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12872198
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588847
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588850
Additional file 1 of Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Henderson, M. X., Sengupta, M., Trojanowski, J. Q., & Lee, V. M. Y. (2019) · Figshare · doi:10.6084/m9.figshare.10316084
Xu, G. M., Fromholt, S., Chakrabarty, P., Zhu, F., Liu, X., Pace, M. C., Koh, J., Golde, T. E., Levites, Y., Lewis, J. M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12097302
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588841
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588829
Scalco, R., Saito, N., Beckett, L. A., Nguyen, M.-L., Huie, E. Z., Wang, H.-P., Flaherty, D., Honig, L. S., DeCarli, C. S., Rissman, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600926
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588853
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588844
Semikasev, E., Ahlemeyer, B., Acker, T., Schänzer, A., & Baumgart‐Vogt, E. (2024) · Figshare · doi:10.6084/m9.figshare.26588832
Featherby, S. J., Faulkner, E. C., Gordon, A. D., & Ettelaie, C. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01658-7
Nguyen, T. T., Vu, Q. X., Tran, T. N. D., Nguyen, T. H., Đoàn, M. D., Xuan, H. B., Tran, T., Vo, C.-V. T., & Nguyen, V. B. (2026) · ChemistrySelect · doi:10.1002/slct.202505919
SPG4 and Dementia: Expanding the Clinical Spectrum
Panza, E., Meyyazhagan, A., Picchi, E., Ribas, G. D. C., Faber, I., Miyamoto, R., Basavaraju, P., Eusebi, P., Bhotla, H. K., Stasi, M., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70371
Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer
Laumet, G. O. (2010) · theses.fr (ABES) · doi:10.70675/94126786zf990z488ezb471z5f1d5686766c
Auboyer, L. (2018) · theses.fr (ABES) · doi:10.70675/07243ef7zb974z4ad8z97d9zd046801798b1
Boudet-Devaud, F. (2018) · theses.fr (ABES) · doi:10.70675/111341b9z5eeez4531z8f07zcb44d6f469a0
Frison, É. (2019) · theses.fr (ABES) · doi:10.70675/a527bd03zb814z44e5z8848z942b662a0847
Arnould, H. (2019) · theses.fr (ABES) · doi:10.70675/9f070729z72aez4fccz9604z8c52be1a62e6
Hayakawa, N., Takeda, S., Takahashi, H., Arisawa, A., Matsuo, C., Tomiyama, N., Nakajima, T., Miki, S., Kishino, Y., Teshirogi, S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261436754
Ribeiro, L. W. (2023) · theses.fr (ABES) · doi:10.70675/68582d99z4406z4ad4zbd76z15927fb63da5
Comorbidities and their Impact on Disease Progression: Focused on Alzheimer's Disease
Sonawane, G., Pansare, K. V., Sonawane, D. D., Patil, C. D., & Mahajan, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010012
Nguyen, L.-Q., Huang, X., Tan, W. Y., Bakar, B. B. A., Huang, J., Venketasubramanian, N., & Hilal, S. (2026) · GeroScience · doi:10.1007/s11357-026-02308-6
Heme–copper–Aβ mediated dopamine oxidation through self-sustaining redox cycling
Dey, C., Pal, P., Khan, A., & Dey, S. G. (2026) · Chemical Communications · doi:10.1039/d6cc03615e
Redox Dysregulation in Neurodegeneration: Molecular Mechanisms and Therapeutic Perspectives
Ramirez-Celis, C., Navarro‐Mabarak, C., Morán, J., & Martínez-Torres, V. S.-M. A. A. M. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016301
Kakkar, A., Singh, H., Anand, A., Mishra, A. K., Chopra, S., Chopra, H., & Greig, N. H. (2026) · Discover Artificial Intelligence · doi:10.1007/s44163-026-01850-8
Synthetic Protein Mimetic Modulators of Tau Aggregation
Lacambra, D. (2026) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2026.169
Creecy, A., Waning, D. L., Khurram, I., Warsame, A., Blosser, R. J., Karnik, S. J., Xu, J., Yamada, C., Smith, D. K., Oblak, A. L., et al. (2026) · GeroScience · doi:10.1007/s11357-026-02569-1
Metadata
- Authors
- Nelson, P. T., Braak, H., & Markesbery, W. R.
- Affiliations
- University of Kentucky HealthCare (US)
- University of Kentucky (US)
- Corresponding author
- Nelson, Peter T.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01
- Volume
- 68
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- PMC
- PMC2692822
- OpenAlex
- W1985747467
- Cited by
- 643
- References
- 155
- Citations by year
- 2026: 21 · 2025: 43 · 2024: 48 · 2023: 46 · 2022: 33 · 2021: 45 · 2020: 44 · 2019: 33 · 2018: 32 · 2017: 32 · 2016: 37 · 2015: 32 · 2014: 35 · 2013: 42 · 2012: 41
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (AG028 383)
- National Institute on Aging (P30AG028383)
- National Institute of Neurological Disorders and Stroke (R01NS061933, K08NS050110)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid plaques, neurofibrillary tangles, cognitive impairment, clinicopathological correlation, Alzheimer's disease diagnosis, Alzheimer disease pathogenesis, autopsy findings
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, Neurofibrillary Tangles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
